Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vivani Medical, Inc.EYES · Entity 6636 | Chief Financial Officer | February 19, 2020 | February 21, 2020 |
| aTYR PHARMA INCLIFE · Entity 7233 | Senior Vice President, Finance | February 06, 2018 | February 09, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vivani Medical, Inc.
Report date February 19, 2020 · Filed February 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,754 |
Ending reported balance
After 2020-02-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-02-19 · Grant · Acquired 2,563 · Balance 2,563 F1: 2,563 shares of common stock acquired upon partial vesting and release of common stock from restricted stock units(RSUs). Row 2 · 2020-02-20 · Disposition to issuer · Disposed 809 · Balance 1,754 F2: 809 shares were sold to satisfy the tax withholding obligations on vesting and release of common stock from RSUs |
| Restricted Stock Units(RSUs)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-02-19 | Direct | 7,687 |
Reported balance
After 2020-02-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-19 · Exercise / conversion · Disposed 2,563 · Balance 7,687 F3: The RSUs vest over four years, in equal annual installments, subject to continuous employment. |
Filing footnotes · ownership attribution and instrument terms
F1: 2,563 shares of common stock acquired upon partial vesting and release of common stock from restricted stock units(RSUs).
F2: 809 shares were sold to satisfy the tax withholding obligations on vesting and release of common stock from RSUs
F3: The RSUs vest over four years, in equal annual installments, subject to continuous employment.
aTYR PHARMA INC
Report date February 06, 2018 · Filed February 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,932 |
Ending reported balance
After 2018-02-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-07 · Exercise / conversion · Acquired 3,334 · Balance 3,334 F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 7, 2017. Row 2 · 2018-02-08 · Sale · Disposed 1,402 · Balance 1,932 F2: Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 7, 2017. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2028-02-06 | Direct | 75,000 |
Reported balance
After 2018-02-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-06 · Grant · Acquired 75,000 · Balance 75,000 F3: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,666 |
Reported balance
After 2018-02-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-07 · Exercise / conversion · Disposed 3,334 · Balance 6,666 F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 7, 2017. F4: The RSU grant vests as to one-third (1/3) of the total number of units on each one year anniversary of the grant commencing on February 7, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 7, 2017.
F2: Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 7, 2017.
F3: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
F4: The RSU grant vests as to one-third (1/3) of the total number of units on each one year anniversary of the grant commencing on February 7, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2020 Filed Feb 21, 2020 22:27 UTC | Vivani Medical, Inc. EYES · Entity 6636 | Disposition to issuerCommon Stock | 809 | $5.44 | $4,400.96 |
DisclosureSEC source: 0001209191-20-011655 · doc4.xml · nonDerivative · entry 2 Blake John T · CIK 0001657162 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,754 F2 · shares: 809 shares were sold to satisfy the tax withholding obligations on vesting and release of common stock from RSUs Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:27 UTC | Vivani Medical, Inc. EYES · Entity 6636 | Exercise / conversionRestricted Stock Units(RSUs) · Derivative | 2,563 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011655 · doc4.xml · derivative · entry 3 Blake John T · CIK 0001657162 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,687 Underlying: Common Stock · 10,250 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The RSUs vest over four years, in equal annual installments, subject to continuous employment. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:27 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantCommon Stock | 2,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011655 · doc4.xml · nonDerivative · entry 1 Blake John T · CIK 0001657162 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,563 F1 · shares: 2,563 shares of common stock acquired upon partial vesting and release of common stock from restricted stock units(RSUs). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 19:16 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantNon-Qualified Stock Option(right to buy) · Derivative | 20,147 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001209191-20-009541 · doc4.xml · derivative · entry 1 Blake John T · CIK 0001657162 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,147 Underlying: Common Stock · 20,147 shares Expires 2030-02-12 F1 · derivative.exercise_date: The stock options have a 10-year term and vest over four years from the grant date in equal monthly installments, subject to continuous employment, such that the total number shall be fully vested on the four-year anniversary of the transaction date. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:24 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantRestricted Stock Units(RSUs) · Derivative | 82,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-012297 · doc4.xml · derivative · entry 2 Blake John T · CIK 0001657162 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 82,000 shares Expires not disclosed F2 · derivative.exercise_date: The RSUs will vest over four years, in equal annual installments, subject to continuous employment. F2 · derivative.expiration_date: The RSUs will vest over four years, in equal annual installments, subject to continuous employment. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:24 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantNon-Qualified Stock Option(right to buy) · Derivative | 163,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-19-012297 · doc4.xml · derivative · entry 1 Blake John T · CIK 0001657162 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,000 Underlying: Common Stock · 163,000 shares Expires 2029-02-19 F1 · derivative.exercise_date: The stock options have a 10-year term and vest over four years from the grant date in equal monthly installments, subject to continuous employment, such that the total number shall be fully vested on the four-year anniversary of the transaction date. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 01:43 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon Stock | 1,402 | $3.40 | $4,766.80 |
DisclosureSEC source: 0001209191-18-008618 · doc4.xml · nonDerivative · entry 2 Blake John T · CIK 0001657162 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,932 F2 · kind: Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 7, 2017. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 01:43 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Units · Derivative | 3,334 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008618 · doc4.xml · derivative · entry 4 Blake John T · CIK 0001657162 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 3,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 7, 2017. F4 · derivative.exercise_date: The RSU grant vests as to one-third (1/3) of the total number of units on each one year anniversary of the grant commencing on February 7, 2018. F4 · derivative.expiration_date: The RSU grant vests as to one-third (1/3) of the total number of units on each one year anniversary of the grant commencing on February 7, 2018. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 01:43 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon Stock | 3,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008618 · doc4.xml · nonDerivative · entry 1 Blake John T · CIK 0001657162 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 7, 2017. Read SEC document |
| February 06, 2018 Filed Feb 9, 2018 01:43 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-18-008618 · doc4.xml · derivative · entry 3 Blake John T · CIK 0001657162 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-02-06 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 21:06 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009051 · doc4.xml · derivative · entry 2 Blake John T · CIK 0001657162 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units (RSUs) are scheduled to vest in three equal annual installments beginning on February 7, 2018, such that this grant will be fully vest on February 7, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The restricted stock units (RSUs) are scheduled to vest in three equal annual installments beginning on February 7, 2018, such that this grant will be fully vest on February 7, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 21:06 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009051 · doc4.xml · derivative · entry 1 Blake John T · CIK 0001657162 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 22:37 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-16-141649 · doc4.xml · derivative · entry 1 Blake John T · CIK 0001657162 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.